Exas - Exact Sciences

Post Reply
PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1550
Joined: Thu Feb 21, 2013 4:00 pm

Exas - Exact Sciences

Posts by PK-TYW » Tue Sep 15, 2020 3:15 pm

ขออณุญาตสร้างกระทู้ใหม่นะครับ หุ้นExas (บริษัทExact Sciences) ทำ2ธุรกิจหลัก cancer screening test(มะเร็งลำไส้ใหญ่) และ Precision Oncology และปัจจุบันทำR&Dเรื่องการตรวจมะเร็งตับ

ซึ่งจุดเด่นคือcostในการตรวจถูกกว่าแบบเก่าและตรวจได้แม่นยำกว่า สามารถตรวจพบตั้งแต่ระยะที่1-2 ซึ่งถ้าตรวจเจอ9ในสิบคนรักษาหายได้ครับ ตอนนี้กินmarketshare5% รายได้เติบโตปีละ50-100% แต่มาสะดุดช่วงcovidที่คนไม่ไปรพ

คำอธิบายของทางบริษัท: Exact Sciences Corporation, a molecular diagnostics company, focuses on developing a molecular diagnostic screening technology for the early detection and prevention of colorectal pre-cancer and cancer. The company develops Cologuard, a stool-based DNA colorectal cancer screening test that is designed to detect each of the four stages of colorectal cancer, as well as pre-cancerous lesions.

official website
https://www.exactsciences.com/

Annual Report
https://www.annualreports.com/HostedDat ... S_2019.pdf

Presentation
http://s22.q4cdn.com/877809405/files/do ... tation.pdf


PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1550
Joined: Thu Feb 21, 2013 4:00 pm

Re: Exas - Exact Sciences

Posts by PK-TYW » Fri Sep 18, 2020 9:35 pm

A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 25.3% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

Exact Sciences' Q2 Earnings Beat, Margin Declines

Exact Sciences incurred loss per share of 58 cents for second-quarter 2020 compared with loss of 30 cents in the year-ago period. However, the reported loss was narrower than the Zacks Consensus Estimate of a loss of 62 cents per share.

Revenues in Detail

Following the completion of the Genomic Health business integration, second-quarter consolidated revenues were $268.9 million, up 34.5% year over year. The metric exceeded the Zacks Consensus Estimate by 17.1%.

Screening revenues were $131.3 million, reflecting a year-over-year decrease of 34%. Precision Oncology revenues were $103 million.

Margin

In the quarter under review, Exact Sciences’ gross profit (excluding the amortization of acquired intangibles) rose 28.4% to $190.9 million. However, gross margin contracted 338 basis points (bps) to 71% on a 52.3% surge in total cost.

Research and development expenses rose 9% year over year to $32.7 million. Sales and marketing expenses rose 34.8% to $118.8 million. General and administrative expenses increased 67.4% to $106.7 million year over year.

Adjusted operating expenses were $258.2 million in the second quarter, up 41.9% year over year. Adjusted operating loss totaled $67.2 million compared with the year-ago operating loss of $33.1 million.

Financial Update

Exact Sciences exited the second quarter of 2020 with cash and cash equivalents of $703.9 million compared with $701.1 million at the end of 2019.

Outlook

Exact Sciences noted that the recent rise in COVID-19 infections has slowed the pace of recovery in its business. Hence, this time too, it has refrained from providing 2020 guidance.


PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1550
Joined: Thu Feb 21, 2013 4:00 pm

Re: Exas - Exact Sciences

Posts by PK-TYW » Fri Sep 18, 2020 9:35 pm

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index was trading around the 3100 level. Stocks kept going up since then. In this article we look at how hedge funds traded EXACT Sciences Corporation (NASDAQ:EXAS) and determine whether the smart money was really smart about this stock.

Is EXACT Sciences Corporation (NASDAQ:EXAS) the right investment to pursue these days? Investors who are in the know were becoming more confident. The number of bullish hedge fund bets went up by 9 recently. EXACT Sciences Corporation (NASDAQ:EXAS) was in 43 hedge funds' portfolios at the end of June. The all time high for this statistics is 41. This means the bullish number of hedge fund positions in this stock currently sits at its all time high.


PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1550
Joined: Thu Feb 21, 2013 4:00 pm

Re: Exas - Exact Sciences

Posts by PK-TYW » Fri Sep 18, 2020 10:20 pm

ARKG 09/17/2020 Buy EXAS 30063P105 EXACT SCIENCES CORP 92,037

ARKG 09/16/2020 Buy EXAS 30063P105 EXACT SCIENCES CORP 264,702

ARKG 09/14/2020 Buy EXAS 30063P105 EXACT SCIENCES CORP 122,419


Post Reply